Acutaas Chemicals Ltd.
ACUTAASHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
20 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 20 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20211030 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220214 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220524 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220817 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221112 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230210 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230519 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230821 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231116 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240216 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240517 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240816 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241105 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250201 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250508 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250805 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251024 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260203 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260506 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260728 | 2026-06-30 | yes |
ACUTAAS
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 3,283.70 |
| 52-week range | 1317.8 – 3694.8 |
| Return 1M | -0.9% |
| Return 3M | -0.49% |
| Return 1Y | 126.59% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 330.00 |
| Other income | 2.00 |
| Total income | 331.00 |
| Cost of materials consumed | 166.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -27.00 |
| Employee benefit expense | 40.00 |
| Finance costs | 1.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.33 | 0.00 |
| institutions foreign | 0.22 | 0.02 |
| institutions domestic | 0.20 | -0.00 |
| mutual funds | 0.14 | 0.00 |
| public | 0.67 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 20 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 147.00 | 152.00 | 186.00 | 142.00 | 172.00 | 166.00 | 225.00 | 177.00 | 247.00 | 275.00 | 308.00 | 207.00 | 306.00 | 393.00 | 433.00 | 330.00 |
| Other income | 1.00 | 3.00 | -0.00 | 1.00 | 2.00 | 3.00 | 1.00 | 1.00 | 8.00 | 2.00 | 6.00 | 16.00 | 10.00 | 5.00 | 11.00 | 2.00 |
| Total income | 148.00 | 155.00 | 186.00 | 143.00 | 174.00 | 170.00 | 226.00 | 178.00 | 255.00 | 277.00 | 314.00 | 223.00 | 316.00 | 398.00 | 444.00 | 331.00 |
| Cost of materials consumed | 59.00 | 125.00 | 105.00 | 70.00 | 148.00 | 86.00 | 134.00 | 105.00 | 143.00 | 157.00 | 165.00 | 104.00 | 131.00 | 176.00 | 184.00 | 166.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 18.00 | -43.00 | 0.00 | 8.00 | -46.00 | 9.00 | 1.00 | -3.00 | -3.00 | -9.00 | -2.00 | -7.00 | 4.00 | -7.00 | -19.00 | -27.00 |
| Employee benefit expense | 13.00 | 13.00 | 11.00 | 14.00 | 16.00 | 16.00 | 17.00 | 19.00 | 20.00 | 22.00 | 23.00 | 25.00 | 29.00 | 30.00 | 33.00 | 40.00 |
| Finance costs | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 2.00 | 4.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Depreciation and amortisation | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 7.00 | 6.00 | 7.00 | 8.00 | 8.00 | 10.00 | 10.00 | 10.00 |
| Other expenses | 30.00 | 26.00 | 29.00 | 25.00 | 30.00 | 29.00 | 30.00 | 26.00 | 39.00 | 37.00 | 38.00 | 34.00 | 46.00 | 43.00 | 52.00 | 38.00 |
| Total expenses | 122.00 | 126.00 | 150.00 | 121.00 | 152.00 | 146.00 | 189.00 | 158.00 | 205.00 | 213.00 | 231.00 | 165.00 | 220.00 | 253.00 | 260.00 | 228.00 |
| Profit before exceptional items and tax | 26.00 | 30.00 | 37.00 | 22.00 | 22.00 | 24.00 | 38.00 | 20.00 | 50.00 | 63.00 | 83.00 | 58.00 | 96.00 | 145.00 | 184.00 | 104.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | -32.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 26.00 | 30.00 | 37.00 | 22.00 | -10.00 | 24.00 | 37.00 | 20.00 | 50.00 | 63.00 | 83.00 | 58.00 | 96.00 | 145.00 | 184.00 | 104.00 |
| Current tax | 6.00 | 6.00 | 9.00 | 5.00 | 6.00 | 5.00 | 9.00 | 5.00 | 12.00 | 17.00 | 16.00 | 13.00 | 19.00 | 36.00 | 49.00 | 27.00 |
| Deferred tax | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 3.00 | 1.00 | 0.00 | 1.00 | 5.00 | 1.00 | 5.00 | 2.00 | 1.00 | 2.00 |
| Tax expense | 7.00 | 7.00 | 9.00 | 6.00 | 7.00 | 6.00 | 12.00 | 5.00 | 12.00 | 18.00 | 20.00 | 14.00 | 24.00 | 38.00 | 50.00 | 29.00 |
| Profit for the period | 19.00 | 22.00 | 27.00 | 17.00 | -17.00 | 18.00 | 26.00 | 15.00 | 38.00 | 45.00 | 63.00 | 44.00 | 72.00 | 106.00 | 134.00 | 75.00 |
| Profit attributable to owners | 0.00 | 0.00 | 0.00 | — | -19.00 | 17.00 | 25.00 | 14.00 | 37.00 | 45.00 | 62.00 | 44.00 | 72.00 | 108.00 | 132.00 | 74.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | — | — | 2.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -2.00 | 3.00 | 1.00 |
| Other comprehensive income | 1.00 | 1.00 | 3.00 | 0.00 | -8.00 | -0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 | 0.00 | -3.00 | -2.00 |
| Total comprehensive income | 20.00 | 23.00 | 31.00 | 17.00 | -25.00 | 18.00 | 26.00 | 15.00 | 37.00 | 45.00 | 63.00 | 44.00 | 72.00 | 106.00 | 131.00 | 73.00 |
| Earnings per share, basic | 5.50 | 6.28 | 7.47 | 4.57 | -4.67 | 4.83 | 6.86 | 3.67 | 9.38 | 11.35 | 7.80 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 |
| Earnings per share, diluted | 5.50 | 6.28 | 7.47 | 4.57 | -4.67 | 4.83 | 6.85 | 3.67 | 9.38 | 11.35 | 7.80 | 5.41 | 8.82 | 13.10 | 16.04 | 9.04 |
Annual results, as filed
| Line | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 520.00 | 617.00 | 717.00 | 1,007.00 | 1,339.00 |
| Other income | 3.00 | 4.00 | 7.00 | 17.00 | 42.00 |
| Total income | 523.00 | 621.00 | 725.00 | 1,024.00 | 1,381.00 |
| Cost of materials consumed | 282.00 | 346.00 | 440.00 | 570.00 | 595.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -9.00 | -15.00 | -28.00 | -18.00 | -29.00 |
| Employee benefit expense | 41.00 | 49.00 | 63.00 | 84.00 | 118.00 |
| Finance costs | 6.00 | 2.00 | 6.00 | 6.00 | 3.00 |
| Depreciation and amortisation | 10.00 | 12.00 | 16.00 | 27.00 | 36.00 |
| Other expenses | 101.00 | 114.00 | 114.00 | 139.00 | 175.00 |
| Total expenses | 431.00 | 509.00 | 611.00 | 808.00 | 898.00 |
| Profit before exceptional items and tax | 91.00 | 112.00 | 114.00 | 216.00 | 483.00 |
| Exceptional items | 0.00 | 0.00 | -32.00 | 0.00 | 0.00 |
| Profit before tax | 91.00 | 112.00 | 82.00 | 216.00 | 483.00 |
| Current tax | 17.00 | 26.00 | 29.00 | 49.00 | 117.00 |
| Deferred tax | 3.00 | 3.00 | 4.00 | 7.00 | 9.00 |
| Tax expense | 20.00 | 29.00 | 33.00 | 56.00 | 126.00 |
| Profit for the period | 72.00 | 83.00 | 49.00 | 160.00 | 356.00 |
| Profit attributable to owners | — | 0.00 | 43.00 | 159.00 | 356.00 |
| Profit attributable to non-controlling interests | — | — | 6.00 | 2.00 | 0.00 |
| Other comprehensive income | 2.00 | 3.00 | -7.00 | -0.00 | -3.00 |
| Total comprehensive income | 74.00 | 86.00 | 41.00 | 160.00 | 353.00 |
| Earnings per share, basic | 21.03 | 22.86 | 11.67 | 19.81 | 43.51 |
| Earnings per share, diluted | 21.03 | 22.86 | 11.66 | 19.81 | 43.37 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 695.00 | 767.00 | 968.00 | 1,096.00 | 1,427.00 | 1,549.00 | 1,696.00 | 1,984.00 |
| Non-current assets | 263.00 | 297.00 | 397.00 | 600.00 | 666.00 | 758.00 | 906.00 | 1,103.00 |
| Current assets | 432.00 | 470.00 | 571.00 | 496.00 | 761.00 | 792.00 | 790.00 | 881.00 |
| Property, plant and equipment | 169.00 | 222.00 | 232.00 | 360.00 | 355.00 | 505.00 | 620.00 | 633.00 |
| Capital work-in-progress | 7.00 | 26.00 | 92.00 | 125.00 | 189.00 | 130.00 | 152.00 | 332.00 |
| Goodwill | 20.00 | 20.00 | 56.00 | 57.00 | 57.00 | 57.00 | 73.00 | 104.00 |
| Other intangible assets | 53.00 | 17.00 | 0.00 | 10.00 | 9.00 | 8.00 | 7.00 | 7.00 |
| Inventories | 161.00 | 119.00 | 164.00 | 157.00 | 158.00 | 180.00 | 191.00 | 231.00 |
| Trade receivables | 172.00 | 230.00 | 206.00 | 206.00 | 242.00 | 290.00 | 291.00 | 363.00 |
| Cash and cash equivalents | 19.00 | 31.00 | 34.00 | 30.00 | 58.00 | 185.00 | 172.00 | 216.00 |
| Total equity and liabilities | 695.00 | 767.00 | 968.00 | 1,096.00 | 1,427.00 | 1,549.00 | 1,696.00 | 1,984.00 |
| Equity | 544.00 | 594.00 | 645.00 | 683.00 | 1,212.00 | 1,320.00 | 1,439.00 | 1,711.00 |
| Equity share capital | 36.00 | 36.00 | 37.00 | 37.00 | 41.00 | 41.00 | 41.00 | 41.00 |
| Other equity | 508.00 | 558.00 | 594.00 | 637.00 | 1,161.00 | 1,269.00 | 1,373.00 | 1,613.00 |
| Total liabilities | 151.00 | 173.00 | 323.00 | 413.00 | 215.00 | 229.00 | 257.00 | 273.00 |
| Non-current liabilities | 8.00 | 10.00 | 54.00 | 128.00 | 19.00 | 27.00 | 37.00 | 42.00 |
| Current liabilities | 142.00 | 163.00 | 269.00 | 285.00 | 196.00 | 202.00 | 219.00 | 231.00 |
| Borrowings, non-current | 0.00 | 1.00 | 43.00 | 114.00 | 3.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 3.00 | 58.00 | 103.00 | 4.00 | 8.00 | 0.00 | 26.00 |
| Trade payables | 122.00 | 142.00 | 173.00 | 135.00 | 148.00 | 156.00 | 149.00 | 154.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 15.00 | 66.00 | 56.00 | 125.00 | 46.00 | 118.00 | 137.00 | 292.00 |
| Net cash from investing activities | 9.00 | -33.00 | -201.00 | -365.00 | -279.00 | -224.00 | -140.00 | -266.00 |
| Net cash from financing activities | -15.00 | -12.00 | 149.00 | 239.00 | 261.00 | 261.00 | -9.00 | 4.00 |
| Purchase of property, plant and equipment | 48.00 | 96.00 | 113.00 | 280.00 | 79.00 | 195.00 | 141.00 | 328.00 |
| Net increase in cash | 9.00 | 20.00 | 4.00 | -1.00 | 28.00 | 156.00 | -13.00 | 30.00 |
| con:CFO.BEFORE_TAX | 24.00 | 90.00 | 76.00 | 150.00 | 66.00 | 165.00 | 165.00 | 404.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 8.00 | 24.00 | 20.00 | 24.00 | 20.00 | 47.00 | 29.00 | 112.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-05-31 | 2024-06-21 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 38.93 | 39.91 | 39.91 | 39.07 | 35.98 | 35.98 | 35.97 | 35.96 | 35.96 | 32.66 | 0.33 | 0.33 | 0.33 | 0.33 |
| Domestic institutions | 5.94 | 7.58 | 6.81 | 8.81 | 14.00 | 14.81 | 19.93 | 20.24 | 18.31 | 22.38 | 0.23 | 0.22 | 0.20 | 0.20 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 16.27 | 0.16 | 0.15 | 0.14 | 0.14 |
| Insurance companies | 0.00 | 0.11 | 0.31 | 0.53 | 2.46 | 3.22 | 4.21 | 4.00 | 2.97 | 4.68 | 0.05 | 0.04 | 0.03 | 0.04 |
| Foreign institutions | 7.16 | 11.65 | 8.97 | 10.01 | 13.14 | 12.92 | 13.87 | 15.52 | 16.48 | 16.94 | 0.17 | 0.17 | 0.19 | 0.22 |
| Government | — | — | — | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 61.07 | 60.09 | 60.09 | 60.93 | 64.02 | 64.02 | 64.03 | 64.04 | 64.04 | 67.34 | 0.67 | 0.67 | 0.67 | 0.67 |
| Non-institutional | 47.97 | 40.86 | 44.31 | 42.12 | 36.87 | 36.29 | 30.23 | 28.27 | 29.23 | 28.01 | 0.28 | 0.29 | 0.28 | 0.26 |
| Shares outstanding | 36880562 | 36880562 | 36880562 | 37679755 | 40905561 | 40905561 | 40927511 | 40934461 | 40934461 | 81868922 | 81868922 | 81871122 | 81871122 | 81871122 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Nareshkumar R. Patel | Managing Director (KMP) | Dividend paid, Remuneration | 37,436,000.00 | 2 |
| Chetankumar C. Vaghasia | Whole Time Director (KMP) | Dividend paid, Remuneration | 33,809,000.00 | 2 |
| Baba Advance Materials Limiteed | Wholly Owned Subsidiary | Any other transaction, Interest received, Loan | 14,499,000.00 | 5 |
| Ami Organics Electrolytes Private Limited | Wholly Owned Subsidiary | Any other transaction, Interest received, Loan | 14,280,000.00 | 4 |
| Sheetalben Patel | Promoter & relative of Directo | Dividend paid | 10,913,000.00 | 1 |
| Ram Mohan Lokhande | Whole Time Director (KMP) | Any other transaction, Remuneration | 9,388,000.00 | 2 |
| Parulben Vaghasia | Promoter & relative of Directo | Dividend paid | 8,813,000.00 | 1 |
| Virendra Nath Mishra | Whole Time Director (KMP) | Dividend paid, Remuneration | 7,601,000.00 | 2 |
| Alkoxide Fine Chem Private Limited | A private company in which a direc | Purchase of goods or services | 4,940,000.00 | 1 |
| Bhavin N. Shah | Chief Financial Officer | Any other transaction, Remuneration | 4,518,000.00 | 2 |
| Ekta Kumari | Company Secretary | Any other transaction, Dividend received, Remunerati | 1,674,000.00 | 3 |
| Bhanuben Vaghasia | Relative KMP | Dividend paid | 1,026,000.00 | 1 |
| Chhagan Vaghasia | Relative KMP | Dividend paid | 1,022,000.00 | 1 |
| Girikrishna Maniar | Independent Director | Any other transaction | 540,000.00 | 1 |
| Hetal M. Gandhi | Independent Director | Any other transaction | 420,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-28 | Q1FY27 | ACUTAAS CHEMICALS LIMITED | Read the call |
| 2026-05-06 | Q4FY26 | ACUTAAS CHEMICALS LIMITED | Read the call |
| 2026-02-03 | Q3FY26 | ACUTAAS CHEMICALS LIMITED, – ACUTAAS CHEMICALS LIMITED | Read the call |
| 2025-10-24 | Q2FY26 | ACUTAAS CHEMICALS LIMITED, – ACUTAAS CHEMICALS LIMITED | Read the call |
| 2025-08-05 | Q1FY26 | ACUTAAS CHEMICALS LIMITED, – ACUTAAS CHEMICALS LIMITED | Read the call |
| 2025-05-08 | Q4FY25 | AMI ORGANICS LIMITED, – AMI ORGANICS LIMITED | Read the call |
| 2025-02-01 | Q3FY25 | AMI ORGANICS LIMITED., DIRECTOR, AMI ORGANICS LIMITED. | Read the call |
| 2024-11-05 | Q2FY25 | AMI ORGANICS LIMITED, DIRECTOR, AMI ORGANICS LIMITED | Read the call |
| 2024-08-16 | Q1FY25 | AMI ORGANICS LIMITED, DIRECTOR, AMI ORGANICS LIMITED | Read the call |
| 2024-05-17 | Q4FY24 | AMI ORGANICS LIMITED | Read the call |
| 2024-02-16 | Q3FY24 | AMI ORGANICS LIMITED, DIRECTOR, AMI ORGANICS LIMITED, ORGANICS LIMITED | Read the call |
| 2023-11-16 | Q2FY24 | LIMITED, MANAGING DIRECTOR | Read the call |
| 2023-08-21 | Q1FY24 | Read the call | |
| 2023-05-19 | Q4FY23 | AMI ORGANICS LIMITED | Read the call |
| 2023-02-10 | Q3FY23 | DIRECTOR, AMI ORGANICS LIMITED | Read the call |
| 2022-11-12 | Q2FY23 | AMI ORGANICS LIMITED | Read the call |
| 2022-08-17 | Q1FY23 | Read the call | |
| 2022-05-24 | Q4FY22 | AMI ORGANICS LIMITED, ANALYST: | Read the call |
| 2022-02-14 | Q3FY22 | AMI ORGANICS LIMITED | Read the call |
| 2021-10-30 | Q2FY22 | AMI ORGANICS LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | As informed in earlier calls about our strategy to fund CAPEX through mix of internal accruals and debt. | Sir, my question is today, what is the capacity utilization, and whatever the CAPEX that we have done in the past. | Due to spill over of second phase of battery chemical capex as well as the pilot plant capex, total capex for the FY '26 is expected to be around INR2… | Currently, we have demolished Ankleshwar unit and work has already started to set up a new plant for pharma intermediates. | I believe we will continue to generate robust cash flow from operation in the coming year as well, which will support our routine opex as well as cape… | Total capex for FY '24 was INR280 crores. | On a capital expenditure side, capex for this financial year stood at INR195 crores, primarily allocated to Ankleshwar site as well as solar and elect… | On Indichem, our South Korea joint venture, while Abhishek will walk you through the capex details, I am pleased to share that the R&D centre is up an… |
| Capital allocation | — | — | On Baba Fine Chem business side, as we discussed last time also, as our endeavor is to promote our products ex of Heraeus business, which we were not … | And Sir the other question from my side is to understand on the growth excluding the acquisition our growth has been quite good at 35%-36% if you can … | Last but not least, we announced the acquisition of 55% stake in Baba Fine Chemicals last month. | Is it acquisition of Baba Fine Chemicals the reason for this goodwill? | — | In parallel, we are actively evaluating land acquisition opportunities to develop new infrastructure that will support our long-term growth ambitions. |
| Costs | As we speak, we are witnessing raw material prices stabilizing. | Apart from the CDMO patented product agreements, raw material prices is stabilized. | — | On the raw material front, all of our export contracts are long-term contracts with built in clauses of escalations to account for movement in KSM pri… | Cost pressures have rationalized to a great extent. | And darolutamide is not a part of our systems in -- from FY '23, but it is part of our system since FY '10 -- '11, so we are very old supplier of this… | A newly commissioned solar plant is projected to deliver substantial annual cost savings by meeting most of the electricity requirement of our company… | On margins, while we remain mindful of the near-term cost pressures stemming from global supply chain disruption. |
| Debt and cash | February 12, 2024 Coming to Cash Flow and Balance Sheet, our working capital for the quarter was stretched during the quarter, mainly driven by lower … | I am happy to share that even with strong growth, we were able to control our working capital, which was 95 days during 9 months FY '25 as against 108… | We have sufficient cash on hand as well as strong cash flow generation to fund this cash outlay. | — | Coming to the balance sheet, we have a net debt-free balance sheet with cash and cash equivalent of around INR59 crores. | On a cash flow and balance sheet side, even during this difficult year, we have been able to keep tight control on our working capital cycle, leading … | I'm happy to share that even with robust growth, we are able to control our working capital, which was 114 days during FY '25 as against 116 days in F… | Our working capital for the year increased to 120 days from 114 days. |
| Demand | This year is expected to be the year of demand recovery following the unforeseen slump in the latter half of 2023. | In Pharma, which is going very well, we have lot of CMO and CDMO in pipelines. | So if you can give some color on the dependency of oncology and how are the other products in the pipeline? | May 17, 2022 capacity at the Sachin unit, where we manufacture the majority of the pharma intermediate, is 65% and we believe that we have enough capa… | On the demand side, we were witnessing gradual upswing in the demand in H2 FY '23. | That is the main aim in the product pipeline. | For battery chemicals, despite moderate demand for electric vehicles globally and delays in new battery cell capacity across the sector, we are observ… | We have successfully commercialized our first two products and have a healthy pipeline of new products in development. |
| Guidance | Consequently, we anticipate a return to standard pricing level in the coming quarters. | So, on the margin side, as you know that we have improved GM by 281 basis points in this financial and EBITDA of 5%, and we expect quarter-on-quarter … | While Q4 will primarily be a quarter of trial production, testing, validation and the commencement of the commercial operations, we expect this busine… | Our sample products are currently with customers across the world and in the best-case scenario, we expect the commercialization of the product by end… | We continue to improve EBITDA margins on a sequential basis as per our guidance. | The ramp-up will be slow in FY '25, but we expect to grow this business by 100% in FY '26 on FY '25 base with capacity expansion of electrolyte additi… | Looking ahead in FY '26, we anticipate continued growth in our CDMO business bolstered by increasing demand and new CDMO contracts. | We expect to bring two additional products to commercial scale in FY27, further strengthening our revenue visibility backed by long-term customer cont… |
| Margin | If you look at our numbers sequentially, they are slightly lower than previous quarter, but if you look at our EBITDA margin, they have expanded by 15… | The gross margin expanded by 333 basis points Y-o-Y, and 281 basis points sequentially to 46.2%. | This is because we have carefully taken strategic decision to review our product portfolio and let go low-margin products. | PAT margin for the full year came at 13.8%. | However, our margins rebounded strongly in H2, and we ended Q4 at 21.9% operating margin. | As guided in previous call, our EBITDA margins continue to grow strongly on sequential basis to deliver strong EBITDA margins of 19.2% for the quarter… | On the margin front, we are committed to deliver further improvements in the margin in FY '26. | We are confident in our ability to maintain EBITDA margin at a similar level in the coming year. underpin our product portfolio upgrade strategy and i… |
| People | Higher employee expenses were driven by yearly increment, ESOP cost and hiring of new employees for Ankleshwar unit. | At Unit-2, 50% capacity utilization we have achieved in Block 3, which is already capitalized. | Sir, what utilization would we be in Ankleshwar? | And what is the exit utilization rate that we are working there? | — | Sir, my question is to understand what would be the utilization across your specialty chemicals under pharma intermediates firms? | Sir, my first question is on the capacity utilization. | First question just wanted to know the capacity utilization for the Sachin plant, the Jagadia plant and the Ankleshwar facility? |
| Pricing | As pricing stabilizes, I am confident our growth will be back to the 20% level. | But whereas here in Specialty Chemical segments where we have some orders, which is deferred to this quarter as well as we also leave some orders base… | Our commodity chemical sub-segment recorded consistent growth driven by high volume stable pricing, which was supported by a recovery in BFC business. | Please note that high inventory for the year is because of stocking up of raw material to secure supply at a better pricing so the majority portion of… | Can you give us an understanding of vinylene carbonates pricing right now, I believe it was trading around $40-odd per kilo. | And last year, as we have mentioned in the past 3 quarters, it was a difficult year for entire industry, so we have seen some pricing pressure also fr… | — | — |
| Revenue growth | 166 crores, which is growth of 9.2% year-on-year. | Moving on to the performance for the 9 months: Ami Organics Limited Jan 29, 2025 Revenue from operations for the 9 months '25 reached INR 698 crores, … | Overall, I believe that FY 2028, these three business verticals will operate as independent self- sustaining growth engines, each contributing meaning… | My question is with respect to the new product which we have developed, so you said the market size is close to a billion dollars and it is expected t… | And now we have some good growth lever lined up which will boost the overall growth of the company. | And as we progress with improved overall prospects for the industry, I firmly believe we will sustain our growth trajectory target, targeting for a re… | Based on these factors, in FY '26, we are confident in delivering 25% revenue growth, a target we have constantly achieved for the past 15 years. | Each contributing meaningful to our top line along with pharmaceutical intermediates business. |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-11-12 | Q2FY23 | AMI ORGANICS LIMITED | We expect to commercialize the product from Q3 and as you all know, Methyl Salicylate is close to 30% of our Specialty Chemicals business and 5% of our total revenue. |
| 2022-11-12 | Q2FY23 | AMI ORGANICS LIMITED | We continue to maintain our guidance of 25% growth in FY '23. |
| 2022-11-12 | Q2FY23 | AMI ORGANICS LIMITED | The gross margin for the quarter was 48%, Employee benefits expense was higher on a sequential as well as on a Y-o-Y basis due to variable pay during the quarter and the annual increment that was rolled out in Q1. We expect this to normalize in second half of FY '23. |
| 2022-11-12 | Q2FY23 | AMI ORGANICS LIMITED | As Naresh bhai mentioned, looking at the demand scenario, we maintained our guidance of 25% growth for FY '23. |
| 2024-05-17 | Q4FY24 | AMI ORGANICS LIMITED | The ramp-up will be slow in FY '25, but we expect to grow this business by 100% in FY '26 on FY '25 base with capacity expansion of electrolyte additives business. |
| 2024-08-16 | Q1FY25 | AMI ORGANICS LIMITED | Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year. |
| 2024-08-16 | Q1FY25 | AMI ORGANICS LIMITED | Overall, we remain on track to achieve our 25% growth target for the year while maintaining healthy EBITDA margins. |
| 2025-10-24 | Q2FY26 | ACUTAAS CHEMICALS LIMITED | One of the reasons of the improvement in the margin is that we started restructuring our existing core pharma intermediate portfolio by churning out low-margin products, at the same time maintaining our growth guidance of 25% for overall business. |
| 2025-10-24 | Q2FY26 | ACUTAAS CHEMICALS LIMITED | To conclude, we are on track to achieve around 25% revenue growth with EBITDA margin expectation to be in the range of 28% to 30% in FY '26. |
| 2026-02-03 | Q3FY26 | ACUTAAS CHEMICALS LIMITED | Due to spill over of second phase of battery chemical capex as well as the pilot plant capex, total capex for the FY '26 is expected to be around INR220 crores versus INR250 crores, which we guided in our previous call. |
| 2026-02-03 | Q3FY26 | ACUTAAS CHEMICALS LIMITED | This shows our CDMO pipeline continued to grow strongly, which will take us swiftly to our CDMO guidance of INR1,000 crores by FY '28. |
| 2026-02-03 | Q3FY26 | ACUTAAS CHEMICALS LIMITED | To conclude, as Naresh bhai guided, we expect revenue from operations to grow by 30% in FY '26. |